Man Group plc Invests $1.09 Million in Disc Medicine, Inc. $IRON

Man Group plc acquired a new stake in Disc Medicine, Inc. (NASDAQ:IRON) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 14,925 shares of the company’s stock, valued at approximately $1,092,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. State of Wyoming bought a new position in Disc Medicine during the 2nd quarter worth approximately $25,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of Disc Medicine in the 4th quarter valued at approximately $33,000. Allworth Financial LP bought a new stake in shares of Disc Medicine in the 2nd quarter valued at approximately $46,000. Persistent Asset Partners Ltd acquired a new stake in shares of Disc Medicine during the 4th quarter valued at approximately $141,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Disc Medicine during the 2nd quarter valued at approximately $153,000. Institutional investors and hedge funds own 83.70% of the company’s stock.

Disc Medicine Price Performance

Shares of IRON opened at $80.05 on Thursday. The company has a market cap of $3.07 billion, a P/E ratio of -12.17 and a beta of 0.98. The stock has a fifty day moving average price of $77.49 and a 200 day moving average price of $70.15. The company has a debt-to-equity ratio of 0.09, a current ratio of 24.14 and a quick ratio of 24.14. Disc Medicine, Inc. has a 12 month low of $40.00 and a 12 month high of $99.50.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, topping the consensus estimate of ($1.71) by $0.17. On average, research analysts forecast that Disc Medicine, Inc. will post -6.61 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have commented on IRON. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Disc Medicine in a report on Tuesday. Wall Street Zen cut shares of Disc Medicine from a “hold” rating to a “sell” rating in a report on Saturday, August 29th. Morgan Stanley restated an “overweight” rating and issued a $90.00 price target on shares of Disc Medicine in a research report on Monday, August 17th. Wedbush lifted their price target on shares of Disc Medicine from $88.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research report on Friday, July 17th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $107.70.

Insider Buying and Selling

In other Disc Medicine news, COO Jonathan Yen-Wen Yu sold 8,796 shares of the business’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $83.12, for a total transaction of $731,123.52. Following the completion of the transaction, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at $4,515,410.88. The trade was a 13.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO John D. Quisel sold 33,000 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $79.15, for a total transaction of $2,611,950.00. Following the completion of the transaction, the chief executive officer owned 226,064 shares of the company’s stock, valued at approximately $17,892,965.60. This trade represents a 12.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 153,612 shares of company stock valued at $11,431,811 in the last quarter. Company insiders own 3.76% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.